CHICAGO (Standard&Poor's) April 22, 2015--Standard&Poor's Ratings Services said today that its ratings and CreditWatch status on Perrigo Co. plc (BBB/Watch Neg/--) are currently not affected by the company's rejection of an unsolicited bid to acquire the company by Mylan N.V. (Mylan), whose principal operating subsidiary is Mylan Inc. (BBB-/Watch Dev/--). We placed the ratings on Perrigo on CreditWatch with negative implications on April 9, 2015, following Mylan's proposal to acquire the company. The ratings and CreditWatch status are also not affected by Teva Pharmaceutical Industries Ltd.'s (A-/Watch Neg/--) proposal to acquire Mylan. We believe the Teva proposal introduces additional uncertainty with respect to consolidation in the generic drug industry, including whether Perrigo will be acquired by
